IARTHIGH SIGNALFINANCIAL10-K

Integra LifeSciences experienced a dramatic deterioration in operating cash flow alongside a near-complete cessation of share buyback activity, signaling potential operational stress.

The substantial decline in operating cash flow combined with minimal share repurchases suggests management is conserving cash amid operational challenges. The company's reduced financial flexibility is further evidenced by lower stockholders' equity and total assets, indicating potential balance sheet pressures that warrant close monitoring.

Comparing 2026-02-26 vs 2025-02-25View on EDGAR →
FINANCIAL ANALYSIS

Integra's financial profile shows concerning cash generation trends with operating cash flow declining substantially while the company pulled back almost entirely from share buybacks. The balance sheet contracted meaningfully with lower total assets and stockholders' equity, though current liabilities also decreased significantly. Despite these pressures, the company continued investing in R&D with a 23% increase, suggesting management remains committed to innovation even as gross profit declined modestly.

FINANCIAL STATEMENT CHANGES
Share Buybacks
Cash Flow
-99.6%
$52.5M$221K

Buyback activity reduced 99.6% — capital being redeployed elsewhere or cash conservation underway.

Operating Cash Flow
Cash Flow
-61.1%
$129.4M$50.4M

Operating cash flow fell 61.1% — earnings quality concerns; investigate working capital changes and non-cash items.

Current Liabilities
Balance Sheet
-50.6%
$922.1M$456.0M

Current liabilities reduced — improved short-term financial position and working capital health.

Stockholders Equity
Balance Sheet
-32.5%
$1.5B$1.0B

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

R&D Expense
P&L
+23%
$63.5M$78.0M

R&D investment increased 23% — signals commitment to future product development, though near-term margin impact.

Capital Expenditure
Cash Flow
-22%
$104.4M$81.4M

Capex reduced 22% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Inventory
Balance Sheet
+14.8%
$429.1M$492.7M

Inventory built 14.8% — monitor whether demand supports this build or if write-downs may follow.

Total Assets
Balance Sheet
-10.8%
$4.0B$3.6B

Total assets contracted 10.8% — asset sales, write-downs, or balance sheet optimization underway.

Gross Profit
P&L
-10.7%
$952.9M$851.0M

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-25
ADDED
Management's Discussion and Analysis of Financial Condition and Results of Operations 40 Item 7A.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 56 Item 13.
BUSINESS OVERVIEW Integra LifeSciences Holdings Corporation is a global medical technology company dedicated to restoring lives.
We are advancing transformational care through impactful innovation and our portfolio of highly differentiated technologies is trusted by healthcare professionals to deliver transformative care.
The CSS segment, which represents approximately 70% of our total revenue, consists of market-leading technologies and instrumentation used for a wide range of specialties, such as neurosurgery, neurocritical care, and otolaryngology, commonly referred to as ear, nose, and throat ( ENT ).
+7 more — sign up free →
REMOVED
Management's Discussion and Analysis of Financial Condition and Results of Operations 38 Item 7A.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matte rs 57 Item 13.
and international governmental, regulatory, fiscal, monetary and public health responses to such crises; and other risk factors described in Item 1A.
BUSINESS OVERVIEW Integra LifeSciences Holdings Corporation was founded in 1989 and is a leading global medical technology company innovating treatment pathways to advance patient outcomes and set new standards of surgical, neurologic, ear, nose, and throat ( ENT ) and regenerative care.
Integra products are sold in more than 120 countries through a direct sales force as well as distributors and wholesalers.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →